Despite extensive evidence supporting EGFR as a therapeutic target in HNSCC, the response rate for single-agent cetuximab is below 20% in this disease [15], and therapy-resistant tumors arise in the majority of cetuximab-treated HNSCC patients [16]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.